Clinical trial
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic…
NCT00292396 · AbbVie (prior sponsor, Abbott), Industry · Completed
Key facts
| NCT number | NCT00292396 |
|---|---|
| Title | Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Official title | A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Subcutaneous Injections of ABT-874 vs. Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Lead sponsor | AbbVie (prior sponsor, Abbott), Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Anti IL-12 monoclonal antibody/ABT-874, placebo |
| Enrollment | 180 |
| Start date | Nov 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Feb 16, 2006 |
| Last update posted | Jan 18, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: